Trial Search Results

Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Medtronic Cardiovascular

Stanford Investigator(s):

Intervention(s):

  • Device: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
  • Device: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)

Phase:

N/A

Eligibility


Inclusion Criteria:

   - Moderate to severe or severe symptomatic mitral regurgitation

   - Local site multidisciplinary heart team experienced in mitral valve therapies agrees
   that the subject is unsuitable for treatment with approved transcatheter repair or
   conventional mitral valve intervention

Exclusion Criteria:

   - prior transcatheter mitral valve procedure with device currently implanted

   - anatomic contraindications

   - prohibitive mitral annular calcification

   - left ventricular ejection fraction <30%

   - need for emergent or urgent surgery

   - hemodynamic instability

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Recruiting